A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers. On Tuesday the company said one of those drugs, cabiralizumab, a Five Prime antibody that Bristol-Myers Squibb (NYSE: BMY) was testing in combination with its cancer immunotherapy nivolumab […]
Original Article: Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test